Thousands of customers are set to receive payments after purchasing a weight loss supplement once described as the "Gastric Bypass Alternative," according to the FTC.

Researchers have mapped human fat tissue at single-cell resolution, uncovering how obesity alters cellular stress, ...

The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Weight loss is known to improve health in obesity. A new study provides clues to how: by rejuvenating fat tissue and changing ...

MariTide, a groundbreaking weight loss medication, shows 16% weight reduction in trials. Learn about this promising monthly ...

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Weight loss injections will not be enough to make “lasting progress” in tackling the obesity epidemic, leading medical ...

Weight loss jabs alone will not be enough to turn the tide on obesity – doctors - An estimated 1.5 million British people are ...

Following a ketogenic diet, modified alternate-day fasting, or late time-restricted eating leads to more weight loss than ...

A GLP-1/glucagon dual agonist conferred weight loss of up to 12.55% at 32 weeks for adults with overweight or obesity, ...